Temat: liposomal irinotecan - Katalog OPAC zbiorów

Skocz do pozycji: 1.

Tytuł:: Cytostatic treatment with irinotecan liposomal in a patient with advanced pancreatic adenocarcinoma
Autorzy:: Będkowski, Przemysław
Rogowski, Wojciech
Powiązania:: https://bibliotekanauki.pl/articles/2047206.pdf
Data publikacji:: 2021-06-30
Wydawca:: Medical Education
Tematy:: pancreatic adenocarcinoma
liposomal irinotecan
chemotherapy
Opis:: Pancreatic cancer is one of the most common malignant neoplasms with a short survival time and a low cure rate. This neoplasm progresses quickly, it is often diagnosed in the advanced stage, which means that systemic treatment regimens are not sufficiently effective. A case of 65-year-old patient with metastatic pancreatic cancer who underwent sequential chemotherapy with the use of liposomal irinotecan was presented.
Źródło:: OncoReview; 2021, 11, 2; 40-43
2450-6125
Pojawia się w:: OncoReview
Dostawca treści:: Biblioteka Nauki

Artykuł

Skocz do pozycji: 2.

Tytuł:: Prolongation of survival time and improvement of the quality of life after treatment with liposomal irinotecan in the patient with metastatic pancreatic adenocarcinoma
Autorzy:: Rogowski, Wojciech
Będkowski, Przemysław
Powiązania:: https://bibliotekanauki.pl/articles/2047214.pdf
Data publikacji:: 2021-07-15
Wydawca:: Medical Education
Tematy:: pancreatic cancer
chemotherapy
gemcitabine
liposomal irinotecan
Opis:: Pancreatic cancer is one of the malignant neoplasms with the worst prognosis. It is most often diagnosed at an advanced stage, which relates to unsatisfactory results of the therapy. Only about 15–20% of patients with pancreatic cancer qualify for surgery. The remaining patients are diagnosed with locally advanced disease or much more frequently in the generalized stage. Systemic treatment (chemotherapy) remains the mainstay of therapy in these patients, but both the response rate and progression-free time are unsatisfactory [1, 2]. This paper presents a case of a patient with metastatic pancreatic cancer, in whom three lines of systemic treatment were applied sequentially, which allowed to extend the survival time and improve the quality of life.
Źródło:: OncoReview; 2021, 11, 3; 77-79
2450-6125
Pojawia się w:: OncoReview
Dostawca treści:: Biblioteka Nauki

Artykuł

Skocz do pozycji: 3.

Tytuł:: Patient with disseminated malignant tumor of the pancreas. Application of liposomal irinotecan as a new option of palliative treatment
Autorzy:: Galińska, Bogumiła
Becht, Rafał
Powiązania:: https://bibliotekanauki.pl/articles/2047218.pdf
Data publikacji:: 2021-07-12
Wydawca:: Medical Education
Tematy:: liposomal irinotecan
malignant neoplasm of the pancreas
pancreatic cancer
Opis:: In palliative treatment of pancreatic neoplasms, chemotherapy regimens with gemcitabine, nab-paclitaxel, oxaliplatin, irinotecan, 5-fluorouracil or combinations of these drugs are used. The registration of liposomal irinotecan in the treatment of stage IV disease in patients with progression after gemcitabine creates new options for the treatment choice. The described case concerns a relatively young patient in whom the use of liposomal irinotecan in the registration indication turned out to be a safe and well-tolerated treatment.
Źródło:: OncoReview; 2021, 11, 3; 73-76
2450-6125
Pojawia się w:: OncoReview
Dostawca treści:: Biblioteka Nauki

Artykuł

Skocz do pozycji: 4.

Tytuł:: Metastatic pancreatic adenocarcinoma treated with liposomal irinotecan in combination with 5-fluorouracil and leucovorin as a II line chemotherapy
Autorzy:: Kraj, Leszek
Gryziak, Maciej
Żurawińska-Grzelka, Ewa
Woźniak, Krzysztof
Powiązania:: https://bibliotekanauki.pl/articles/2047205.pdf
Data publikacji:: 2021-06-30
Wydawca:: Medical Education
Tematy:: II line chemotherapy
liposomal irinotecan
leucovorin
peripheral polyneuropathy
overall survival
pancreatic cancer
Opis:: The paper presents a case of a 54-year-old man with pancreatic tumor and intraperitoneal dissemination. The patient received treatment with gemcitabine in combination with nab-paclitaxel. After 18 months, the disease progressed, therefore the line of treatment was applied in the form of liposomal irinotecan with 5-FU/LV. This therapy provided progression-free survival for 7 months. The obtained results are better than the median progression-free survival obtained in the studies. This case demonstrates that liposomal irinotecan in the treatment of stage IV disease in patients progressing after gemcitabine opens up new treatment options.
Źródło:: OncoReview; 2021, 11, 2; 44-47
2450-6125
Pojawia się w:: OncoReview
Dostawca treści:: Biblioteka Nauki

Artykuł

Informacja